Increases to CEO Compensation Might Be Put On Hold For Now at Otonomy, Inc. (NASDAQ:OTIC)
The underwhelming share price performance of Otonomy, Inc. ( NASDAQ:OTIC ) in the past three years would have...
Simply Wall St. · 1d ago
Otonomy shares rise after initiating expansion of early-stage OTO-413 hearing loss trial
Otonomy (OTIC) announces the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.Shares up more than 10% premarket.OTO-413 is a proprietary, sustained-exposure formulation
Seekingalpha · 2d ago
BRIEF-Otonomy Initiates Expansion Of Phase 1/2 Clinical Trial For OTO-413 In Hearing Loss · 2d ago
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohort Expansion study will support endpoint selection and powering for
Benzinga · 2d ago
Otonomy Launches Expansion Study of Drug Candidate for Speech-in-Noise Hearing Loss
MT Newswires · 2d ago
BRIEF-Otonomy Inc Says On May 28, Co Entered Into Asset Purchase Agreement With Alk-Abelló Inc · 06/03 12:18
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients
, /PRNewswire/ -- ALK (), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced today that it has acquired OTIPRIO (ciprofloxacin otic suspension) from Otonomy, Inc. OTIPRIO is a prescription ...
PR Newswire - PRF · 06/03 12:01
Otonomy Insights: Return On Capital Employed
In Q1, Otonomy (NASDAQ:OTIC) posted sales of $90.00 thousand. Earnings were up 15.13%, but Otonomy still reported an overall loss of $11.84 million. Otonomy collected $53.00 thousand in revenue during Q4, but reported earnings showed a $10.29 million loss....
Benzinga · 06/02 13:55
Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows
Benzinga · 05/14 18:59
Otonomy's OTO-825 Gene Therapy Saves Hearing Loss in Preclinical Models
MT Newswires · 05/14 14:14
Otonomy: OTO-825 Rescues Hearing and Cochlear Damage in Preclinical Models
By Michael Dabaie Otonomy Inc. Friday said preclinical proof-of-concept results demonstrate a single administration of OTO-825 rescues hearing loss and... · 05/14 12:32
Otonomy, Applied Genetic Technologies present OTO-825 results in hearing loss
Otonomy (OTIC) announces preclinical proof-of-concept results for OTO-825 at the ASGCT Annual Meeting. OTO-825 is an AAV-mediated gene therapy developed in collaboration with Applied Genetic Technologies Corporation (AGTC).The results demonstrate
Seekingalpha · 05/14 12:02
BRIEF-Otonomy And Agtc Present Preclinical Proof-Of-Concept Results For Oto-825 Gene Therapy At Asgct Annual Meeting · 05/14 11:35
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell Therapy (AS...
GlobeNewswire · 05/14 11:30
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
H.C. Wainwright Thinks Otonomy’s Stock is Going to Recover
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Otonomy (OTIC) today and set a price target of $5.50. The company's shares closed last
SmarterAnalyst · 05/12 10:16
(EDGAR Online via COMTEX) -- false 0001493566 0001493566 2021-05-11 2021-05-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/12 00:37
Otonomy EPS in-line, beats on revenue
Otonomy (OTIC): Q1 GAAP EPS of -$0.23 in-line.Revenue of $0.09M (-43.8% Y/Y) beats by $0.06M.Press Release
Seekingalpha · 05/11 21:03
Recap: Otonomy Q1 Earnings
Shares of Otonomy (NASDAQ:OTIC) rose after the company reported Q1 results. Quarterly Results Earnings per share increased 39.47% year over year to ($0.23), which missed the estimate of ($0.21).
Benzinga · 05/11 20:34
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
GlobeNewswire · 05/11 20:18
Webull provides a variety of real-time OTIC stock news. You can receive the latest news about Otonomy through multiple platforms. This information may help you make smarter investment decisions.
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.